A collection of PDX models derived from triple negative breast cancer patients with residual disease post neoadjuvant chemotherapy
Emerging evidence shows that non-genetic mechanisms play an important role in therapy resistance, however, the resultant intra-tumour transcriptional heterogeneity in residual tumours post neoadjuvant chemotherapy (NAC) treatment and its association with resistance are not yet fully understood. To characterise chemotherapy resistant associated cell populations that may persist post NAC, we created a high-resolution single cell RNA atlas of fourteen patient-derived xenograft (PDX) models generated from triple negative breast cancer patients with residual disease post NAC.